Business Wire

NY-JEFFERIES-FINANCIAL

28.5.2020 18:04:07 CEST | Business Wire | Press release

Share
Jefferies' Clients, Employees and Shareholders Contribute $9,250,000 to Over 85 Charities for Coronavirus Relief in Memory of Peg Broadbent

Jefferies announced today a total donation to over 85 different charities of $9.25 million as a result of a firmwide global effort to raise money to honor the memory of their late CFO Peg Broadbent, who was a victim of this terrible disease.

Through the firm’s Global Coronavirus Relief Charity Day held May 27th, Jefferies’ clients helped to generate $7.65 million in donated net trading commissions. In addition, Jefferies as a firm will donate $1 million directly, and voluntary donations from Jefferies’ 3,822 employees totaled $600,000.

“We could not be prouder of our entire Jefferies family for raising $9.25 million and are greatly appreciative of the incredible partnership our clients have shown us in supporting our fight against Covid-19. The full $9.25 million will be wired today and go to direct relief efforts at over 85 worthy global charities who are each in the front lines helping those most impacted by the Coronavirus global pandemic. We went broadly to a large number of charities globally as this is truly a tragedy that affects all of us and, in particular, those who are most disadvantaged and in the greatest need.

The charities selected are both big and small and represent everything from food banks, child care services, assistance with PPE and other medical supplies, support for front line medical workers, assistance for afflicted military personnel, local teen centers, support for police and fire, workforce training and re-training and many other worthy areas that are most in need. We thank our employees and clients for aiding in the selection of many of these remarkable charities.

Finally, all of us at Jefferies would like to thank all the dedicated professionals working tirelessly on the front line to help those in need. They are the true heroes whom we are honored to help in Peg’s name.”

Contributions in the following amounts will be immediately distributed to these respected organizations:

NYC Mayor’s Fund | Peg’s Cure

 

$ 150,000

All Hands and Hearts

 

$ 150,000

American Heart Association

$ 150,000

Bowery Mission

$ 150,000

Hackensack Meridian Health Foundation

$ 150,000

Houston Police Foundation

 

$ 150,000

International Rescue Committee

 

$ 150,000

Robin Hood Foundation

 

$ 150,000

Strive

 

$ 150,000

The Bass Foundation

 

$ 150,000

World Central Kitchen

 

$ 150,000

We Can #TogetherFromHome

 

$ 100,000

Achievement First

 

$ 100,000

Aktion Deutschland Hilft

 

$ 100,000

Alzheimer’s Association

 

$ 100,000

Ambitious About Autism

 

$ 100,000

Barnardo’s

$ 100,000

BMS Family Health and Wellness Center

 

$ 100,000

Bob Woodruff Foundation

 

$ 100,000

Boys & Girls Clubs of the Austin Area

 

$ 100,000

Brewers Community Foundation

 

$ 100,000

Buttle UK

 

$ 100,000

Central Texas Food Bank

 

$ 100,000

Chelsea and Westminster Hospital NHS Foundation Trust

 

$ 100,000

Chrysalis

$ 100,000

City Harvest

$ 100,000

Citymeals on Wheels

 

$ 100,000

Columbia Children's Hospital

 

$ 100,000

Community Food Bank of New Jersey

 

$ 100,000

Covenant House

 

$ 100,000

Doctors Without Borders

 

$ 100,000

East High – EOP (Education Partnership Organization)

 

$ 100,000

Elmhurst Hospital Charity

 

$ 100,000

Family Promise of Bergen County

 

$ 100,000

FarmLink

 

$ 100,000

Feeding America

 

$ 100,000

Food Bank For New York City

 

$ 100,000

Foodlink

 

$ 100,000

Habitat for Humanity Japan

 

$ 100,000

Hance Family Foundation

 

$ 100,000

Humanity & Inclusion

 

$ 100,000

Hunger Free America

 

$ 100,000

Imperial Health Charity

 

$ 100,000

Kids in Crisis

 

$ 100,000

Kohka Foundation

 

$ 100,000

Lahey Clinic Foundation

 

$ 100,000

Mail Force Charity

 

$ 100,000

Martha’s Table

 

$ 100,000

Médecins Sans Frontières

 

$ 100,000

Memorial Hermann Foundation

 

$ 100,000

My Sister's Place

 

$ 100,000

National Emergencies Trust

 

$ 100,000

Navajo Nation Covid-19 Relief Fund

 

$ 100,000

Nazareth Housing

 

$ 100,000

Neighbourly Community Fund

 

$ 100,000

NHS Charities Together

 

$ 100,000

Northwell Health's COVID-19 Emergency Fund

 

$ 100,000

NYU Langone

 

$ 100,000

Off Their Plate

 

$ 100,000

Oxfam India

 

$ 100,000

Philippine Disaster Resilience Foundation

 

$ 100,000

Red Hook Initiative

 

$ 100,000

Rosetree Trust

 

$ 100,000

Royal College of Nursing Foundation

 

$ 100,000

RVNAhealth

 

$ 100,000

Second Harvest

 

$ 100,000

Sempre Con Voi (Always with You)

 

$ 100,000

St Michael’s House

 

$ 100,000

TBD 1

 

$ 100,000

TBD 2

 

$ 100,000

TBD 3

 

$ 100,000

TCF Bank

 

$ 100,000

The Care Workers Charity

 

$ 100,000

The River Fund New York

 

$ 100,000

The United Way of Central Indiana COVID-19 Relief Fund

 

$ 100,000

The World Health Organization (WHO)

 

$ 100,000

Trinity's Services & Food for the Homeless

 

$ 100,000

The Trussell Trust

 

$ 100,000

UNICEF

 

$ 100,000

UR Medicine Home Care’s Meals on Wheels

 

$ 100,000

URMC COVID-19 Emergency Fund

 

$ 100,000

Valpo Surf Project, Inc.

 

$ 100,000

Volunteers of Legal Service

 

$ 100,000

Our Dream Their Smile

 

$ 100,000

West Side Campaign Against Hunger

 

$ 100,000

Women United in Philanthropy

 

$ 100,000

Women's Center of Greater Danbury

 

$ 100,000

 

 


$ 9,250,000

Jefferies Group LLC is the largest independent, global, full-service investment banking firm headquartered in the U.S. Focused on serving clients for nearly 60 years, Jefferies is a leader in providing insight, expertise and execution to investors, companies and governments. Our firm provides a full range of investment banking, advisory, sales and trading, research and wealth management services across all products in the Americas, Europe and Asia. Jefferies Group LLC is a wholly owned subsidiary of Jefferies Financial Group Inc. (NYSE: JEF), a diversified financial services company.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye